Monthly Archives: December 2017

Goldman Econ Reveals Top Charts Of 2017: It’s All About Goldilock...

Here’s the thing: Goldman wanted to drive home the “Goldilocks” narrative one more time before Christmas. As a reminder, “Goldilocks” is the foundation upon which Wall Street’s constructive 2018 outlooks are built. There are only a few ways you can justify being constructive on anything in an environment where stocks, bonds, and credit are all…

4 Transportation Stocks That Could Beat The Market In 2018

It is a well-established fact that the widely-diversified transportation sector including airline companies, railroads, truckers, shippers to name a few, has struggled for the better part of 2017. Sector participants have been plagued by a number of headwinds like disruptions from back-to-back hurricanes, the devastating earthquake in Mexico, declining automotive volumes, issues related to customer…

Cryptocurrencies Rip Higher As Dip-Buying Replaces Panic-Selling

Yesterday’s triple-legged panic-selling across the crypto-space, which saw Bitcoin and Ethereum down 30 and 40% respectively at their worst ended around 10 am ET and while the mainstream media was happy to declare (once again) the death of Bitcoin et al., the entire crypto world has soared since – almost erasing the entire day’s losses. Across the board,…

Energy ETFs Head To Head: XLE Vs. IYE

The energy sector has been attracting a lot of investor attention lately. Oil prices have been relatively stable lately, owing to the recent supply cut extension by OPEC. What Lies Ahead for Crude? OPEC recently extended its production cut till late 2018, in order to drive crude prices. Moreover, talks of OPEC working on an…

Top Trading Opportunities For 2018

The Euro is running out of reasons to rise, inflation might push the BoE to hike which can boost the British Pound, and a supply glut might send crude oil lower. What else in 2018? Short: EUR vs. USD, GBP – The Euro is Running Out of Reasons to Rise By Ilya Spivak, Senior Strategist The Euro enjoyed an undeniably…

Week In Review: Nearly $2 Billion Late-December Week For China Ph

Nanjing Legend Biotech received a $350 million upfront payment from Janssen Biotech, which will form a global partnership with Legend for its highly effective CAR-T candidate (see story). In June, Legend, which was not previously well known, surprised the annual ASCO meeting with stunningly positive results from an early trial of the CAR-T molecule in patients…